HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cigarette pre-emption claims up in smoke

This article was originally published in The Tan Sheet

Executive Summary

The Supreme Court rules 5-4 that smokers can sue tobacco companies alleging advertising for "light" cigarettes was deceptive, rejecting Philip Morris' argument that state law claims are pre-empted by the Federal Cigarette Labeling and Advertising Act. The court says there is no conflict between state law and federal law, which neither expressly nor implicitly pre-empts fraud claims. The decision does not reveal how the court will rule in Wyeth v. Levine, concerning the drug industry's defense that FDA labeling regulations pre-empt state tort claims (1"The Tan Sheet" Nov. 10, 2008, p. 20). In a sign the cases are different, the U.S. Solicitor General submitted a brief opposing Philip Morris' claim, but argues for pre-emption in Wyeth v. Levine

You may also be interested in...



Supreme Court Ruling In Wyeth Case May Make FDA More Cautious

How the U.S. Supreme Court rules in Wyeth v. Levine could limit the number of product liability suits brought against drug companies

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel